One in 400 children are born with a genetic mutation that causes hearing loss. Tel Aviv University scientists have developed a harmless synthetic virus that replaces defective genes with healthy genes. It may prevent deafness when injected into the inner … Continue reading →

Preliminary data from Phase 2 trials of opaganib from Israel’s Redhill (reported here previously) on 40 hospitalized Covid-19 patients showed positive results. Patients receiving opaganib had significantly reduced dependence on ventilators and faster time to discharge. https://www.prnewswire.com/il/news-releases/redhill-s-phase-2-3-covid-19-candidate-opaganib-reduces-ards-related-blood-clotting-in-preclinical-model-813822864.html